Aveanna Healthcare (AVAH) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue reached $520 million, up 8.6% year-over-year, with adjusted EBITDA of $55.2 million, a 42.8% increase, driven by improved payer rates and cost reductions.

• Full year 2024 revenue was $2.024 billion, up 6.8%, and adjusted EBITDA was $183.6 million, up 31.9% from the prior year.

• Q4 net income was $29.2 million versus a net loss of $25.7 million in Q4 2023; full-year net loss narrowed to $10.9 million from $134.5 million.

• Strategic focus on preferred payers, government rate improvements, and cost reductions led to solid growth and improved hiring and retention trends.

• Achieved 12 state rate increases and expanded preferred payer agreements from 14 to 22 in private duty services.

Financial highlights

• Q4 consolidated gross margin was $171.7 million (33%), with all three segments showing revenue growth: private duty services up 10.1%, medical solutions up 4.8%, and home health and hospice up 0.6%.

• Q4 private duty services revenue was $422.2 million, with a 4% volume increase and revenue per hour up 6.1%.

• Q4 home health and hospice revenue was $54.4 million, with 8,500 admissions and 76% episodic mix.

• Q4 medical solutions revenue was $43.3 million, with gross margin at 44.3%, up 10.5% year-over-year.

• Q4 benefited from $6.5 million in one-time items: $3 million timing-related rate enhancement and $3.5 million insurance reserve true-up.

Outlook and guidance

• 2025 revenue guidance is $2.1–$2.12 billion, with adjusted EBITDA of $190–$194 million, including a 53rd week in Q4.

• Q1 2025 expected to be seasonally lower due to payroll taxes and post-holiday effects, with EBITDA building in later quarters.

• Guidance is described as prudent, with expectations for continued margin expansion, organic volume growth, and growth in preferred payer agreements.